Lung Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

  • Published : Jul-2017
  • Tables : 236
  • Figures : 68
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT49MR
  • Format : ppt

Lung cancer or lung carcinoma is malignant maturation of lung tumor, caused by uncontrolled growth of cells & tissues in the lung. Lung cancer diagnostics can be defined as an umbrella of tests & diagnosis procedures used in treatment of lung cancer, which includes methods such as imaging, tumor screening, sputum cytology tests, and biopsy.

Fact.MR, in its recent report, estimates the global lung cancer diagnostics market to register an impressive 7.3% CAGR during the forecast period 2017 to 2022.

The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in lung cancer-specific biomarkers. These diagnostic tools are expected to facilitate personalized treatment approach towards lung malignancies. A number of biomarkers exist in the research pipeline. In the recent past, Epigenomics AG launched a new test based on blood utilizing DNA methylation biomarkers, whose developments are in the process. The initial results obtained from these tests have promised early diagnosis of lung cancer. Such incidences are expected to increase demand for lung cancer diagnostics across the globe.

Increasing Awareness Programs for Lung Cancer to Drive Growth of the Market

A number of awareness programs associated with lung cancer and its related symptoms have been initiated in order to enhance the diagnosis and screening rates of individuals with high risks of developing lung malignancies. For example – In the United Kingdom, November is considered to be the lung cancer awareness month, and is supported by Roy Castle Lung Cancer Foundation. Such initiatives help in raising awareness about early detection and diagnosis of lung cancer.

CA tests will continue to be the most lucrative tests for lung cancer diagnostics in the market. Revenue from CA tests will account for US$ 889.3 Mn by 2022-end. Angiogenesis inhibitor is expected to witness the fastest expansion among test type in the market, followed by HER 2 tests. Revenue from ALK tests for lung cancer diagnostics will continue to remain low in the market.

Market Taxonomy

Test Type

End User

Indication

CA Test

Hospital Associated Labs

Non Small-cell Lung Cancer

HER2 Tests

Independent Diagnostic Laboratories

Small-cell Lung Cancer

ALK Tests

Cancer Research Institutes

 

Angiogenesis Inhibitor

Others

 

EGFR Mutation Tests

   

KRAS Mutation Tests

   

Others

   

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Hospital-associated Labs to Remain the Most Lucrative End-Users of Lung Cancer Diagnostics

Hospital-associated labs will remain the most lucrative end-users of lung cancer diagnostics in the global market, with revenues estimated to reach nearly US$ 1,500 Mn by 2022-end. Cancer research institutes will continue to exhibit the fastest expansion in the global lung cancer diagnostics market, followed by independent diagnostic laboratories. In addition, independent diagnostic laboratories are expected to be the second largest end-users of lung cancer diagnostics throughout the forecast period.

On the basis of indication, although non-small cell lung cancer is expected to remain sought-after in the market, small cell-lung cancer is expected to exhibit the fastest expansion through 2022. Revenue from non-small cell lung cancer is expected to remain largest during the forecast period. In contrast, revenue from small cell lung cancer will continue to be low in the global lung cancer diagnostics market.

Competition Tracking

Novel product launches for lung cancer diagnostics is a key strategy adopted by leading players in the global market, in order to increase their product portfolio. Fact.MR’s report profiles key market players, which include Illumina, Inc., Abbott Laboratories, Thermo Fischer Scientific, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, and Danaher Corporation.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Chapter 1. Global Lung Cancer Diagnostics Market - Executive Summary. 12

Chapter 2. Global Lung Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
       2.1.1. Global Lung Cancer Diagnostics Market Taxonomy. 14
       2.1.2. Global Lung Cancer Diagnostics Market Definition. 14
2.2. Global Lung Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
       2.2.1. Global Lung Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Lung Cancer Diagnostics Market Dynamics. 15
       2.3.1. Drivers. 15
       2.3.2. Restraints. 15
       2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Key Participants Market Presence (Intensity Map) By Region. 16

Chapter 3. Global Lung Cancer Diagnostics Market Analysis and Forecast By Test Type. 17
3.1. Global Lung Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 17
       3.1.1. CA Test Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 17
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 17
                3.1.1.2. Market Share Comparison, By Region. 19
                3.1.1.3. Y-o-Y growth Comparison, By Region. 19
       3.1.2. HER2 Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 20
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 20
                3.1.2.2. Market Share Comparison, By Region. 22
                3.1.2.3. Y-o-Y growth Comparison, By Region. 22
       3.1.3. ALK Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 23
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 23
                3.1.3.2. Market Share Comparison, By Region. 25
                3.1.3.3. Y-o-Y growth Comparison, By Region. 25
       3.1.4. Angiogenesis Inhibitor Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
                3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 26
                3.1.4.2. Market Share Comparison, By Region. 28
                3.1.4.3. Y-o-Y growth Comparison, By Region. 28
       3.1.5. EGFR Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
                3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 29
                3.1.5.2. Market Share Comparison, By Region. 31
                3.1.5.3. Y-o-Y growth Comparison, By Region. 31
       3.1.6. KRAS Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
                3.1.6.1. Revenue (US$ Mn) Comparison, By Region. 32
                3.1.6.2. Market Share Comparison, By Region. 34
                3.1.6.3. Y-o-Y growth Comparison, By Region. 34
       3.1.7. Others Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
                3.1.7.1. Revenue (US$ Mn) Comparison, By Region. 35
                3.1.7.2. Market Share Comparison, By Region. 37
                3.1.7.3. Y-o-Y growth Comparison, By Region. 37

Chapter 4. Global Lung Cancer Diagnostics Market Analysis and Forecast By End User. 39
4.1. Global Lung Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 39
       4.1.1. Hospital Associated Labs Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 39
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 39
                4.1.1.2. Market Share Comparison, By Region. 41
                4.1.1.3. Y-o-Y growth Comparison, By Region. 41
       4.1.2. Independent Diagnostic Laboratories Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 42
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 42
                4.1.2.2. Market Share Comparison, By Region. 44
                4.1.2.3. Y-o-Y growth Comparison, By Region. 44
       4.1.3. Cancer Research Institutes Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 45
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 45
                4.1.3.2. Market Share Comparison, By Region. 47
                4.1.3.3. Y-o-Y growth Comparison, By Region. 47
       4.1.4. Others Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 48
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 48
                4.1.4.2. Market Share Comparison, By Region. 50
                4.1.4.3. Y-o-Y growth Comparison, By Region. 50

Chapter 5. Global Lung Cancer Diagnostics Market Analysis and Forecast By Indication. 52
5.1. Global Lung Cancer Diagnostics Market Size and Forecast By Indication, 2012-2022. 52
       5.1.1. Non Small-cell Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 52
                5.1.1.1. Revenue (US$ Mn) Comparison, By Region. 52
                5.1.1.2. Market Share Comparison, By Region. 54
                5.1.1.3. Y-o-Y growth Comparison, By Region. 54
       5.1.2. Small-cell Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
                5.1.2.1. Revenue (US$ Mn) Comparison, By Region. 55
                5.1.2.2. Market Share Comparison, By Region. 57
                5.1.2.3. Y-o-Y growth Comparison, By Region. 57

Chapter 6. Global Lung Cancer Diagnostics Market Analysis and Forecast By Region. 59
6.1. Global Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 59
       6.1.1. North America Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 59
                6.1.1.1. Revenue (US$ Mn) Comparison, By Test Type. 59
                6.1.1.2. Revenue (US$ Mn) Comparison, By End User. 61
                6.1.1.3. Revenue (US$ Mn) Comparison, By Indication. 62
       6.1.2. Latin America Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
                6.1.2.1. Revenue (US$ Mn) Comparison, By Test Type. 64
                6.1.2.2. Revenue (US$ Mn) Comparison, By Indication. 67
       6.1.3. Europe Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 69
                6.1.3.1. Revenue (US$ Mn) Comparison, By Test Type. 69
                6.1.3.2. Revenue (US$ Mn) Comparison, By End User. 71
                6.1.3.3. Revenue (US$ Mn) Comparison, By Indication. 72
       6.1.4. Japan Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 74
                6.1.4.1. Revenue (US$ Mn) Comparison, By Test Type. 74
                6.1.4.2. Revenue (US$ Mn) Comparison, By Indication. 77
       6.1.5. APEJ Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 79
                6.1.5.1. Revenue (US$ Mn) Comparison, By Test Type. 79
                6.1.5.2. Revenue (US$ Mn) Comparison, By End User. 81
                6.1.5.3. Revenue (US$ Mn) Comparison, By Indication. 82
       6.1.6. MEA Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 84
                6.1.6.1. Revenue (US$ Mn) Comparison, By Test Type. 84
                6.1.6.2. Revenue (US$ Mn) Comparison, By End User. 86
                6.1.6.3. Revenue (US$ Mn) Comparison, By Indication. 87

Chapter 7. North America Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 90
7.1. US Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 90
       7.1.1. Revenue (US$ Mn) Comparison, By Test Type. 90
       7.1.2. Revenue (US$ Mn) Comparison, By End User. 91
       7.1.3. Revenue (US$ Mn) Comparison, By Indication. 91
7.2. Canada Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 92
       7.2.1. Revenue (US$ Mn) Comparison, By Test Type. 92
       7.2.2. Revenue (US$ Mn) Comparison, By End User. 93
       7.2.3. Revenue (US$ Mn) Comparison, By Indication. 94

Chapter 8. Latin America Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 96
8.1. Brazil Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 96
       8.1.1. Revenue (US$ Mn) Comparison, By Test Type. 96
       8.1.2. Revenue (US$ Mn) Comparison, By End User. 97
       8.1.3. Revenue (US$ Mn) Comparison, By Indication. 97
8.2. Mexico Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 98
       8.2.1. Revenue (US$ Mn) Comparison, By Test Type. 98
       8.2.2. Revenue (US$ Mn) Comparison, By End User. 99
       8.2.3. Revenue (US$ Mn) Comparison, By Indication. 100
8.3. Argentina Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 101
       8.3.1. Revenue (US$ Mn) Comparison, By Test Type. 101
       8.3.2. Revenue (US$ Mn) Comparison, By End User. 102
       8.3.3. Revenue (US$ Mn) Comparison, By Indication. 103

Chapter 9. Europe Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 104
9.1. Germany Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 104
       9.1.1. Revenue (US$ Mn) Comparison, By Test Type. 104
       9.1.2. Revenue (US$ Mn) Comparison, By End User. 105
       9.1.3. Revenue (US$ Mn) Comparison, By Indication. 106
9.2. UK Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 106
       9.2.1. Revenue (US$ Mn) Comparison, By Test Type. 106
       9.2.2. Revenue (US$ Mn) Comparison, By End User. 107
       9.2.3. Revenue (US$ Mn) Comparison, By Indication. 108
9.3. France Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 109
       9.3.1. Revenue (US$ Mn) Comparison, By Test Type. 109
       9.3.2. Revenue (US$ Mn) Comparison, By End User. 110
       9.3.3. Revenue (US$ Mn) Comparison, By Indication. 111
9.4. Spain Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 111
       9.4.1. Revenue (US$ Mn) Comparison, By Test Type. 111
       9.4.2. Revenue (US$ Mn) Comparison, By End User. 112
       9.4.3. Revenue (US$ Mn) Comparison, By Indication. 113
9.5. Italy Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 114
       9.5.1. Revenue (US$ Mn) Comparison, By Test Type. 114
       9.5.2. Revenue (US$ Mn) Comparison, By End User. 115
       9.5.3. Revenue (US$ Mn) Comparison, By Indication. 116
9.6. Nordic Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 116
       9.6.1. Revenue (US$ Mn) Comparison, By Test Type. 116
       9.6.2. Revenue (US$ Mn) Comparison, By End User. 117
       9.6.3. Revenue (US$ Mn) Comparison, By Indication. 118

Chapter 10. Japan Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 120
10.1. Japan  Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 120
       10.1.1. Revenue (US$ Mn) Comparison, By Test Type. 120
       10.1.2. Revenue (US$ Mn) Comparison, By End User. 121
       10.1.3. Revenue (US$ Mn) Comparison, By Indication. 121

Chapter 11. APEJ Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 123
11.1. China Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 123
       11.1.1. Revenue (US$ Mn) Comparison, By Test Type. 123
       11.1.2. Revenue (US$ Mn) Comparison, By End User. 124
       11.1.3. Revenue (US$ Mn) Comparison, By Indication. 124
11.2. India Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 125
       11.2.1. Revenue (US$ Mn) Comparison, By Test Type. 125
       11.2.2. Revenue (US$ Mn) Comparison, By End User. 126
       11.2.3. Revenue (US$ Mn) Comparison, By Indication. 127
11.3. Malaysia Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 128
       11.3.1. Revenue (US$ Mn) Comparison, By Test Type. 128
       11.3.2. Revenue (US$ Mn) Comparison, By End User. 129
       11.3.3. Revenue (US$ Mn) Comparison, By Indication. 130
11.4. Thailand Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 130
       11.4.1. Revenue (US$ Mn) Comparison, By Test Type. 130
       11.4.2. Revenue (US$ Mn) Comparison, By End User. 131
       11.4.3. Revenue (US$ Mn) Comparison, By Indication. 132
11.5. Singapore Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 133
       11.5.1. Revenue (US$ Mn) Comparison, By Test Type. 133
       11.5.2. Revenue (US$ Mn) Comparison, By End User. 134
       11.5.3. Revenue (US$ Mn) Comparison, By Indication. 135
11.6. Australia Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 136
       11.6.1. Revenue (US$ Mn) Comparison, By Test Type. 136
       11.6.2. Revenue (US$ Mn) Comparison, By End User. 137
       11.6.3. Revenue (US$ Mn) Comparison, By Indication. 137

Chapter 12. MEA Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 139
12.1. GCC Countries Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 139
       12.1.1. Revenue (US$ Mn) Comparison, By Test Type. 139
       12.1.2. Revenue (US$ Mn) Comparison, By End User. 140
       12.1.3. Revenue (US$ Mn) Comparison, By Indication. 141
12.2. South Africa Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 141
       12.2.1. Revenue (US$ Mn) Comparison, By Test Type. 141
       12.2.2. Revenue (US$ Mn) Comparison, By End User. 142
       12.2.3. Revenue (US$ Mn) Comparison, By Indication. 143
12.3. Nigeria Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 144
       12.3.1. Revenue (US$ Mn) Comparison, By Test Type. 144
       12.3.2. Revenue (US$ Mn) Comparison, By End User. 145
       12.3.3. Revenue (US$ Mn) Comparison, By Indication. 146
12.4. Israel Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 146
       12.4.1. Revenue (US$ Mn) Comparison, By Test Type. 146
       12.4.2. Revenue (US$ Mn) Comparison, By End User. 147
       12.4.3. Revenue (US$ Mn) Comparison, By Indication. 148

Chapter 13. Global Lung Cancer Diagnostics Market Company/Manufactures/Distributors/Suppliers Profile and Revenue Projections. 150
13.1. Illumina, Inc.. 150
       13.1.1. Company Overview. 150
       13.1.2. Product Overview. 151
       13.1.3. Key Financials. 151
       13.1.4. Key Developments. 151
       13.1.5. SWOT Analysis. 151
13.2. Abbott Laboratories. 153
       13.2.1. Company Overview. 153
       13.2.2. Product Overview. 153
       13.2.3. Key Financials. 153
       13.2.4. Key Developments. 154
       13.2.5. SWOT Analysis. 154
13.3. Thermo Fisher Scientific, Inc. 155
       13.3.1. Company Overview. 155
       13.3.2. Product Overview. 155
       13.3.3. Key Financials. 155
       13.3.4. Key Developments. 156
       13.3.5. SWOT Analysis. 156
13.4. QIAGEN N.V.. 157
       13.4.1. Company Overview. 157
       13.4.2. Product Overview. 157
       13.4.3. Key Financials. 158
13.5. Quest Diagnostics Incorporated. 159
       13.5.1. Company Overview. 159
       13.5.2. Product Overview. 159
       13.5.3. Key Financials. 159
       13.5.4. SWOT Analysis. 160
13.6. NeoGenomics Laboratories, Inc.. 162
       13.6.1. Company Overview. 162
       13.6.2. Key Financials. 162
13.7. NanoString Technologies Inc. 163
       13.7.1. Company Overview. 163
       13.7.2. Product Overview. 163
       13.7.3. Key Financials. 164
13.8. Myriad Genetics Inc. 165
       13.8.1. Company Overview. 165
       13.8.2. Product Overview. 165
       13.8.3. Key Financials. 166
       13.8.4. SWOT Analysis. 166
13.9. Roche Holding AG.. 169
       13.9.1. Company Overview. 169
       13.9.2. Product Overview. 169
       13.9.3. Key Financials. 170
       13.9.4. Key Developments. 170
       13.9.5. SWOT Analysis. 170
13.10. Danaher Corporation. 174
       13.10.1. Company Overview. 174
       13.10.2. Product Overview. 174
       13.10.3. Key Financials. 175
       13.10.4. Key Developments. 175
       13.10.5. SWOT Analysis. 175

TABLE 1 Global Lung Cancer Diagnostics Market Value (US$ Mn), 2012-2016 29
TABLE 2 Global Lung Cancer Diagnostics Market Value (US$ Mn), 2017-2022 30
TABLE 3 Global Lung Cancer Diagnostics Market Value (US$ Mn) and Y-o-Y, 2015-2022 32
TABLE 4 Global CA Test Segment Value (US$ Mn), By Region 2012-2016 34
TABLE 5 Global CA Test Segment Value (US$ Mn), By Region 2017-2022 35
TABLE 6 Global CA Test Segment Market Share, By Region 2012-2016 36
TABLE 7 Global CA Test Segment Market Share, By Region 2017-2022 36
TABLE 8 Global CA Test Segment Y-o-Y, By Region 2015-2022 36
TABLE 9 Global HER2 Tests Segment Value (US$ Mn), By Region 2012-2016 37
TABLE 10 Global HER2 Tests Segment Value (US$ Mn), By Region 2017-2022 38
TABLE 11 Global HER2 Tests Segment Market Share, By Region 2012-2016 39
TABLE 12 Global HER2 Tests Segment Market Share, By Region 2017-2022 39
TABLE 13 Global HER2 Tests Segment Y-o-Y, By Region 2015-2022 39
TABLE 14 Global ALK Tests Segment Value (US$ Mn), By Region 2012-2016 40
TABLE 15 Global ALK Tests Segment Value (US$ Mn), By Region 2017-2022 41
TABLE 16 Global ALK Tests Segment Market Share, By Region 2012-2016 42
TABLE 17 Global ALK Tests Segment Market Share, By Region 2017-2022 42
TABLE 18 Global ALK Tests Segment Y-o-Y, By Region 2015-2022 42
TABLE 19 Global Angiogenesis Inhibitor Segment Value (US$ Mn), By Region 2012-2016 43
TABLE 20 Global Angiogenesis Inhibitor Segment Value (US$ Mn), By Region 2017-2022 44
TABLE 21 Global Angiogenesis Inhibitor Segment Market Share, By Region 2012-2016 45
TABLE 22 Global Angiogenesis Inhibitor Segment Market Share, By Region 2017-2022 45
TABLE 23 Global Angiogenesis Inhibitor Segment Y-o-Y, By Region 2015-2022 45
TABLE 24 Global EGFR Mutation Tests Segment Value (US$ Mn), By Region 2012-2016 46
TABLE 25 Global EGFR Mutation Tests Segment Value (US$ Mn), By Region 2017-2022 47
TABLE 26 Global EGFR Mutation Tests Segment Market Share, By Region 2012-2016 48
TABLE 27 Global EGFR Mutation Tests Segment Market Share, By Region 2017-2022 48
TABLE 28 Global EGFR Mutation Tests Segment Y-o-Y, By Region 2015-2022 48
TABLE 29 Global KRAS Mutation Tests Segment Value (US$ Mn), By Region 2012-2016 49
TABLE 30 Global KRAS Mutation Tests Segment Value (US$ Mn), By Region 2017-2022 50
TABLE 31 Global KRAS Mutation Tests Segment Market Share, By Region 2012-2016 51
TABLE 32 Global KRAS Mutation Tests Segment Market Share, By Region 2017-2022 51
TABLE 33 Global KRAS Mutation Tests Segment Y-o-Y, By Region 2015-2022 51
TABLE 34 Global Others Segment Value (US$ Mn), By Region 2012-2016 52
TABLE 35 Global Others Segment Value (US$ Mn), By Region 2017-2022 53
TABLE 36 Global Others Segment Market Share, By Region 2012-2016 54
TABLE 37 Global Others Segment Market Share, By Region 2017-2022 54
TABLE 38 Global Others Segment Y-o-Y, By Region 2015-2022 54
TABLE 39 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2012-2016 56
TABLE 40 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2017-2022 57
TABLE 41 Global Hospital Associated Labs Segment Market Share, By Region 2012-2016 58
TABLE 42 Global Hospital Associated Labs Segment Market Share, By Region 2017-2022 58
TABLE 43 Global Hospital Associated Labs Segment Y-o-Y, By Region 2015-2022 58
TABLE 44 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2012-2016 59
TABLE 45 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2017-2022 60
TABLE 46 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2012-2016 61
TABLE 47 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2017-2022 61
TABLE 48 Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2015-2022 61
TABLE 49 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2012-2016 62
TABLE 50 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2017-2022 63
TABLE 51 Global Cancer Research Institutes Segment Market Share, By Region 2012-2016 64
TABLE 52 Global Cancer Research Institutes Segment Market Share, By Region 2017-2022 64
TABLE 53 Global Cancer Research Institutes Segment Y-o-Y, By Region 2015-2022 64
TABLE 54 Global Others Segment Value (US$ Mn), By Region 2012-2016 65
TABLE 55 Global Others Segment Value (US$ Mn), By Region 2017-2022 66
TABLE 56 Global Others Segment Market Share, By Region 2012-2016 67
TABLE 57 Global Others Segment Market Share, By Region 2017-2022 67
TABLE 58 Global Others Segment Y-o-Y, By Region 2015-2022 67
TABLE 59 Global Non Small-cell Lung Cancer Segment Value (US$ Mn), By Region 2012-2016 69
TABLE 60 Global Non Small-cell Lung Cancer Segment Value (US$ Mn), By Region 2017-2022 70
TABLE 61 Global Non Small-cell Lung Cancer Segment Market Share, By Region 2012-2016 71
TABLE 62 Global Non Small-cell Lung Cancer Segment Market Share, By Region 2017-2022 71
TABLE 63 Global Non Small-cell Lung Cancer Segment Y-o-Y, By Region 2015-2022 71
TABLE 64 Global Small-cell Lung Cancer Segment Value (US$ Mn), By Region 2012-2016 72
TABLE 65 Global Small-cell Lung Cancer Segment Value (US$ Mn), By Region 2017-2022 73
TABLE 66 Global Small-cell Lung Cancer Segment Market Share, By Region 2012-2016 74
TABLE 67 Global Small-cell Lung Cancer Segment Market Share, By Region 2017-2022 74
TABLE 68 Global Small-cell Lung Cancer Segment Y-o-Y, By Region 2015-2022 74
TABLE 69 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 76
TABLE 70 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 77
TABLE 71 North America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 78
TABLE 72 North America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 78
TABLE 73 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 79
TABLE 74 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 80
TABLE 75 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 81
TABLE 76 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 82
TABLE 77 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 83
TABLE 78 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 83
TABLE 79 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 84
TABLE 80 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 85
TABLE 81 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 86
TABLE 82 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 87
TABLE 83 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 88
TABLE 84 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 88
TABLE 85 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 89
TABLE 86 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 90
TABLE 87 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 91
TABLE 88 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 92
TABLE 89 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 93
TABLE 90 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 93
TABLE 91 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 94
TABLE 92 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 95
TABLE 93 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 96
TABLE 94 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 97
TABLE 95 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 98
TABLE 96 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 98
TABLE 97 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 99
TABLE 98 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 100
TABLE 99 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 101
TABLE 100 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 102
TABLE 101 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 103
TABLE 102 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 103
TABLE 103 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 104
TABLE 104 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 105
TABLE 105 US Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 107
TABLE 106 US Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 107
TABLE 107 US Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 108
TABLE 108 US Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 108
TABLE 109 US Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 108
TABLE 110 US Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 109
TABLE 111 Canada Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 109
TABLE 112 Canada Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 110
TABLE 113 Canada Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 110
TABLE 114 Canada Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 111
TABLE 115 Canada Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 111
TABLE 116 Canada Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 111
TABLE 117 Brazil Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 113
TABLE 118 Brazil Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 113
TABLE 119 Brazil Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 114
TABLE 120 Brazil Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 114
TABLE 121 Brazil Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 114
TABLE 122 Brazil Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 115
TABLE 123 Mexico Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 115
TABLE 124 Mexico Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 116
TABLE 125 Mexico Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 116
TABLE 126 Mexico Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 117
TABLE 127 Mexico Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 117
TABLE 128 Mexico Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 117
TABLE 129 Argentina Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 118
TABLE 130 Argentina Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 118
TABLE 131 Argentina Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 119
TABLE 132 Argentina Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 119
TABLE 133 Argentina Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 120
TABLE 134 Argentina Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 120
TABLE 135 Germany Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 121
TABLE 136 Germany Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 121
TABLE 137 Germany Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 122
TABLE 138 Germany Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 122
TABLE 139 Germany Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 123
TABLE 140 Germany Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 123
TABLE 141 UK Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 123
TABLE 142 UK Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 124
TABLE 143 UK Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 124
TABLE 144 UK Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 125
TABLE 145 UK Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 125
TABLE 146 UK Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 125
TABLE 147 France Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 126
TABLE 148 France Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 126
TABLE 149 France Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 127
TABLE 150 France Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 127
TABLE 151 France Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 128
TABLE 152 France Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 128
TABLE 153 Spain Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 128
TABLE 154 Spain Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 129
TABLE 155 Spain Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 129
TABLE 156 Spain Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 130
TABLE 157 Spain Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 130
TABLE 158 Spain Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 130
TABLE 159 Italy Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 131
TABLE 160 Italy Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 131
TABLE 161 Italy Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 132
TABLE 162 Italy Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 132
TABLE 163 Italy Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 133
TABLE 164 Italy Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 133
TABLE 165 Nordic Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 133
TABLE 166 Nordic Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 134
TABLE 167 Nordic Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 134
TABLE 168 Nordic Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 135
TABLE 169 Nordic Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 135
TABLE 170 Nordic Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 135
TABLE 171 Japan  Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 137
TABLE 172 Japan  Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 137
TABLE 173 Japan  Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 138
TABLE 174 Japan  Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 138
TABLE 175 Japan  Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 138
TABLE 176 Japan  Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 139
TABLE 177 China Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 140
TABLE 178 China Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 140
TABLE 179 China Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 141
TABLE 180 China Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 141
TABLE 181 China Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 141
TABLE 182 China Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 142
TABLE 183 India Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 142
TABLE 184 India Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 143
TABLE 185 India Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 143
TABLE 186 India Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 144
TABLE 187 India Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 144
TABLE 188 India Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 144
TABLE 189 Malaysia Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 145
TABLE 190 Malaysia Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 145
TABLE 191 Malaysia Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 146
TABLE 192 Malaysia Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 146
TABLE 193 Malaysia Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 147
TABLE 194 Malaysia Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 147
TABLE 195 Thailand Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 147
TABLE 196 Thailand Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 148
TABLE 197 Thailand Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 148
TABLE 198 Thailand Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 149
TABLE 199 Thailand Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 149
TABLE 200 Thailand Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 149
TABLE 201 Singapore Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 150
TABLE 202 Singapore Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 150
TABLE 203 Singapore Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 151
TABLE 204 Singapore Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 151
TABLE 205 Singapore Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 152
TABLE 206 Singapore Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 152
TABLE 207 Australia Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 153
TABLE 208 Australia Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 153
TABLE 209 Australia Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 154
TABLE 210 Australia Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 154
TABLE 211 Australia Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 154
TABLE 212 Australia Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 155
TABLE 213 GCC Countries Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 156
TABLE 214 GCC Countries Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 156
TABLE 215 GCC Countries Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 157
TABLE 216 GCC Countries Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 157
TABLE 217 GCC Countries Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 158
TABLE 218 GCC Countries Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 158
TABLE 219 South Africa Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 158
TABLE 220 South Africa Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 159
TABLE 221 South Africa Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 159
TABLE 222 South Africa Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 160
TABLE 223 South Africa Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 160
TABLE 224 South Africa Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 160
TABLE 225 Nigeria Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 161
TABLE 226 Nigeria Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 161
TABLE 227 Nigeria Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 162
TABLE 228 Nigeria Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 162
TABLE 229 Nigeria Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 163
TABLE 230 Nigeria Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 163
TABLE 231 Israel Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 163
TABLE 232 Israel Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 164
TABLE 233 Israel Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 164
TABLE 234 Israel Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 165
TABLE 235 Israel Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 165
TABLE 236 Israel Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 165

FIG. 1 Global Lung Cancer Diagnostics Market Value (US$ Mn), 2012-2016 18
FIG. 2 Global Lung Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2022 18
FIG. 3 Global Lung Cancer Diagnostics Market Value (US$ Mn) and Y-o-Y, 2015-2022 20
FIG. 4 Global CA Test Segment Market Value (US$ Mn) By Region, 2012-2016 22
FIG. 5 Global CA Test Segment Market Value (US$ Mn) By Region, 2017-2022 23
FIG. 6 Global CA Test Segment Y-o-Y Growth Rate, By Region, 2015-2022 25
FIG. 7 Global HER2 Tests Segment Market Value (US$ Mn) By Region, 2012-2016 25
FIG. 8 Global HER2 Tests Segment Market Value (US$ Mn) By Region, 2017-2022 26
FIG. 9 Global HER2 Tests Segment Y-o-Y Growth Rate, By Region, 2015-2022 28
FIG. 10 Global ALK Tests Segment Market Value (US$ Mn) By Region, 2012-2016 28
FIG. 11 Global ALK Tests Segment Market Value (US$ Mn) By Region, 2017-2022 29
FIG. 12 Global ALK Tests Segment Y-o-Y Growth Rate, By Region, 2015-2022 31
FIG. 13 Global Angiogenesis Inhibitor Segment Market Value (US$ Mn) By Region, 2012-2016 31
FIG. 14 Global Angiogenesis Inhibitor Segment Market Value (US$ Mn) By Region, 2017-2022 32
FIG. 15 Global Angiogenesis Inhibitor Segment Y-o-Y Growth Rate, By Region, 2015-2022 34
FIG. 16 Global EGFR Mutation Tests Segment Market Value (US$ Mn) By Region, 2012-2016 34
FIG. 17 Global EGFR Mutation Tests Segment Market Value (US$ Mn) By Region, 2017-2022 35
FIG. 18 Global EGFR Mutation Tests Segment Y-o-Y Growth Rate, By Region, 2015-2022 37
FIG. 19 Global KRAS Mutation Tests Segment Market Value (US$ Mn) By Region, 2012-2016 37
FIG. 20 Global KRAS Mutation Tests Segment Market Value (US$ Mn) By Region, 2017-2022 38
FIG. 21 Global KRAS Mutation Tests Segment Y-o-Y Growth Rate, By Region, 2015-2022 40
FIG. 22 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016 40
FIG. 23 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022 41
FIG. 24 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022 43
FIG. 25 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2012-2016 44
FIG. 26 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2017-2022 45
FIG. 27 Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2015-2022 47
FIG. 28 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2012-2016 47
FIG. 29 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2017-2022 48
FIG. 30 Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2015-2022 50
FIG. 31 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2012-2016 50
FIG. 32 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2017-2022 51
FIG. 33 Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2015-2022 53
FIG. 34 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016 53
FIG. 35 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022 54
FIG. 36 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022 56
FIG. 37 Global Non Small-cell Lung Cancer Segment Market Value (US$ Mn) By Region, 2012-2016 57
FIG. 38 Global Non Small-cell Lung Cancer Segment Market Value (US$ Mn) By Region, 2017-2022 58
FIG. 39 Global Non Small-cell Lung Cancer Segment Y-o-Y Growth Rate, By Region, 2015-2022 60
FIG. 40 Global Small-cell Lung Cancer Segment Market Value (US$ Mn) By Region, 2012-2016 60
FIG. 41 Global Small-cell Lung Cancer Segment Market Value (US$ Mn) By Region, 2017-2022 61
FIG. 42 Global Small-cell Lung Cancer Segment Y-o-Y Growth Rate, By Region, 2015-2022 63
FIG. 43 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 64
FIG. 44 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 65
FIG. 45 North America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 66
FIG. 46 North America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 67
FIG. 47 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 68
FIG. 48 North America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 68
FIG. 49 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 69
FIG. 50 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 70
FIG. 51 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 71
FIG. 52 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 72
FIG. 53 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 73
FIG. 54 Latin America Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 73
FIG. 55 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 74
FIG. 56 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 75
FIG. 57 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 76
FIG. 58 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 77
FIG. 59 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 78
FIG. 60 Europe Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 78
FIG. 61 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 79
FIG. 62 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 80
FIG. 63 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 81
FIG. 64 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 82
FIG. 65 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 83
FIG. 66 Japan Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 83
FIG. 67 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 84
FIG. 68 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 85
FIG. 69 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 86
FIG. 70 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 87
FIG. 71 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 88
FIG. 72 APEJ Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 88
FIG. 73 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 89
FIG. 74 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 90
FIG. 75 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 91
FIG. 76 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 92
FIG. 77 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2012-2016 93
FIG. 78 MEA Lung Cancer Diagnostics Market Value (US$ Mn), By Indication 2017-2022 93

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development